Form 4: Teladoc CFO Sells Shares for Tax Obligations

Teladoc Health's Chief Financial Officer, Mala Murthy, sold 12,846 shares of common stock to cover tax withholding obligations related to the vesting of performance and restricted stock units.

Summary

• Mala Murthy, Chief Financial Officer of Teladoc Health, Inc. (TDOC), reported transactions under a Rule 10b5-1 plan.
• On August 29, 2025, Murthy acquired a total of 22,788 shares of Teladoc Health common stock through the conversion of performance stock units (2,641 shares) and restricted stock units (20,147 shares).
• Performance stock units and restricted stock units convert to common stock on a one-for-one basis.
• Following these acquisitions, Murthy's direct beneficial ownership of common stock increased to 155,231 shares.
• On September 2, 2025, Murthy sold 12,846 shares of common stock at a price of $7.585 per share.
• The sale was executed to cover tax withholding obligations arising from the vesting of the performance stock unit and restricted stock unit awards.
• After the sale, Murthy's direct beneficial ownership of common stock stands at 142,385 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the reported transactions are routine insider activities related to equity compensation and tax obligations, executed under a pre-planned Rule 10b5-1 arrangement, and do not indicate a change in company fundamentals or management's outlook.

Positives

• The vesting of performance stock units and restricted stock units indicates the achievement of performance milestones or continued service, resulting in compensation for the Chief Financial Officer.

Negatives

• The sale of 12,846 shares, while for tax purposes, reduces the Chief Financial Officer's direct equity stake in the company.

Future Outlook

The filing does not provide specific forward-looking statements or guidance regarding the company's financial performance or strategic direction, focusing solely on insider stock transactions.

Industry Context

This insider transaction report is a routine disclosure of executive compensation and tax-related stock sales, which is common across all publicly traded companies and does not inherently reflect broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: The sale represents a minor dilution of the executive's direct ownership, but it is a routine tax-related transaction and unlikely to significantly impact shareholder sentiment or the company's stock price.
• Employees: The vesting of equity awards demonstrates the company's compensation structure for executives, which may be viewed positively by employees as a sign of performance-based rewards.

Next Steps

• The remaining portions of the performance stock units will vest in eight substantially equal quarterly installments after March 1, 2024.
• The remaining portions of certain restricted stock units will vest in eight substantially equal quarterly installments beginning on June 1, 2025.

Key Dates

Recommendation

The filing details routine insider transactions related to equity compensation and tax obligations, executed under a pre-planned Rule 10b5-1 arrangement. It does not contain new information regarding the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this filing alone does not alter the fundamental investment thesis for Teladoc Health.

Keywords

Teladoc Health, TDOC, Insider Transaction, Form 4, CFO, Stock Sale, Restricted Stock Units, Performance Stock Units, Equity Compensation, Tax Withholding